Denali Therapeutics Inc. DNLI Business Segments — Other selling, general and administrative expenses

Similar metrics at other companies

SLABReportable Segment — Other selling, general and administrative expenses

$41.71M+51.5%

CHWYReportable Segment — Other selling, general, and administrative expenses

$208.5M+4.9%

KOR

KOREReportable Segment — Other selling, general, and administrative expenses

$2.69M+150%

SIT

SITEReportable Segment — Other Selling, general and administrative expenses

$34.3M+8.2%

MAMAReportable Segment — Other selling, general, and administrative expenses

$6.43M+26.1%

TPRStuart Weitzman — Other selling, general and administrative expenses

$0-100%

FAQ

What is Denali Therapeutics Inc.'s business segments — other selling, general and administrative expenses?

Denali Therapeutics Inc. (DNLI) reported business segments — other selling, general and administrative expenses of $13.36M in Q2 2026.

What does business segments — other selling, general and administrative expenses mean?

This metric captures non-personnel operating expenses associated with the therapeutics segment, such as facility overhead, legal fees, professional services, and administrative infrastructure costs. It provides insight into the indirect costs required to sustain the business operations of the drug development pipeline outside of direct R&D or payroll. Tracking these expenses allows for an evaluation of the company's ability to manage overhead costs while scaling its therapeutic development efforts.